Librela for dogs: How the injection works

When your dog is struggling with joint pain and stiffness, finding the right treatment can feel overwhelming. Librela has emerged as a significant breakthrough in canine arthritis management, offering a completely different approach to traditional pain medications. This monthly injection targets pain signals in a novel way, providing relief for many dogs where other treatments may have fallen short.

However, recent safety updates have highlighted important considerations that every dog owner should understand before choosing this treatment. Whilst Librela continues to help thousands of dogs live more comfortably, emerging data about potential side effects means informed decision-making with your vet is more crucial than ever.

Understanding how Librela works, its benefits, and the latest safety information will help you have meaningful conversations with your veterinary team about whether this treatment is right for your dog.

Comparing joint support options alongside Librela treatment

When your vet has prescribed Librela for your dog's arthritis, you might wonder what other support options could work alongside this monthly injection. We've compared MedPaw Hip & Joint Chews Max (our product) with five other popular joint supplements to help you understand what each brings to the table.

The comparison reveals that MedPaw is the only supplement containing all six key joint actives that research suggests may support cartilage health and joint comfort. For dogs receiving Librela, this comprehensive nutritional support could be particularly valuable as the injection focuses specifically on pain signals rather than joint structure itself.

While Librela targets nerve growth factor to reduce pain messages, a complete joint supplement like MedPaw provides glucosamine, chondroitin, MSM, green-lipped mussel, hyaluronic acid and Boswellia serrata - ingredients that may support the underlying joint tissues. The soft chew format makes daily dosing straightforward alongside your monthly vet visits.

Explore MedPaw Hip & Joint Chews Max Complete joint nutrition with our 60-day money-back guarantee.

What Makes Librela Different

Librela contains bedinvetmab, a monoclonal antibody that represents a genuinely revolutionary approach to managing arthritis pain in dogs. Unlike traditional anti-inflammatory medications such as meloxicam or carprofen, Librela doesn't work by reducing inflammation in the joints.

Instead, it targets nerve growth factor (NGF), a protein that plays a crucial role in generating and amplifying pain signals from arthritic joints. By binding to NGF and blocking its activity, Librela reduces the pain messages reaching your dog's brain without affecting the inflammatory process itself.

This different mechanism offers several potential advantages. Dogs who experience gastrointestinal upset with traditional NSAIDs may tolerate Librela better, as it doesn't affect the stomach lining in the same way. The monthly injection format also eliminates the daily tablet routine, which can be particularly helpful for dogs who are difficult to medicate or owners who struggle with consistent daily dosing.

How the Treatment Works

Your vet administers Librela as a simple injection under the skin once monthly. The medication then circulates in your dog's system, continuously blocking NGF for approximately four weeks. This provides sustained pain relief without the peaks and troughs that can occur with daily medications.

The injection is available in different strengths based on your dog's weight, from 5mg for smaller dogs up to 30mg for larger breeds. Most dogs tolerate the injection well, with minimal discomfort at the injection site.

Clinical Evidence and Effectiveness

Research demonstrates encouraging results for most dogs treated with Librela. Clinical trials have shown that dogs receiving the treatment experienced significantly greater pain reduction compared to those given a placebo injection.

In controlled studies, treatment success rates improved from 36% at two weeks to 50% by eight weeks, compared to much lower success rates in dogs receiving placebo injections. These improvements were measured using validated pain assessment tools that evaluate mobility, willingness to exercise, and overall comfort levels.

Perhaps most significantly, recent research found Librela to be as effective as meloxicam, one of the most commonly prescribed NSAIDs for canine arthritis. This represents a meaningful finding, as achieving similar results to established treatments through a completely different mechanism provides valuable options for dogs who cannot tolerate traditional medications.

Long-term Use

Clinical studies and post-market data show that dogs can safely remain on Librela for extended periods under veterinary supervision. Some dogs have received continuous monthly treatment for over a year with maintained effectiveness and good tolerance.

However, regular reassessment remains essential to ensure ongoing benefit and monitor for any developing concerns. Your vet should evaluate your dog's response and overall health at regular intervals throughout treatment.

Recent Safety Concerns

Whilst Librela has proven effective for many dogs, post-marketing surveillance has identified some important safety considerations that have led to updated warnings and guidance from regulators.

Neurological Side Effects

In December 2024, the US Food and Drug Administration issued a formal warning following reports of neurological adverse events in dogs treated with Librela. These included unsteadiness (particularly affecting the hind legs), seizures, partial paralysis, urinary incontinence, and excessive thirst and urination.

The FDA's review examined 363 dogs with multiple neurological signs, with approximately 73% being over 10 years old. This age group already carries higher risk of underlying neurological conditions, which may complicate the assessment of whether symptoms are treatment-related.

Based on global data covering over 18 million doses administered, these neurological events are classified as rare to very rare, occurring in approximately 1 to 10 dogs per 10,000 treated. However, the potential severity of these effects has prompted increased vigilance from both regulators and veterinary professionals.

Musculoskeletal Concerns

More concerning findings emerged in 2025 regarding potential effects on bones and joints. Research examining European pharmacovigilance data found that ligament and tendon injuries, fractures, and joint inflammation were reported approximately nine times more frequently in Librela-treated dogs compared to those receiving other arthritis medications.

A detailed case series of 19 dogs reviewed by expert veterinary specialists raised particular concerns about accelerated joint destruction. The panel found strong evidence suggesting a causal relationship between bedinvetmab and progressive joint changes in these cases.

The changes observed included significant new bone formation around joints, soft tissue turning to bone (ossification), and in some severe cases, joint dislocation. These findings have prompted updated warnings and closer monitoring recommendations.

UK Regulatory Response

In February 2026, the UK Veterinary Medicines Directorate completed an in-depth safety assessment and concluded that Librela's benefits continue to outweigh risks for most dogs when used appropriately. However, the product information was updated with important new warnings to help vets and owners make more informed decisions.

The updated labelling now includes joint swelling, joint pain, bone and joint disorders, and soft tissue ossification as very rare adverse events (affecting fewer than 1 animal in 10,000 treated). The warnings specifically describe new bone formation around joints that can occur with repeated administration, may affect single or multiple joints, can be progressive, and in very rare cases has been associated with fractures.

Enhanced Monitoring Recommendations

The regulator now specifically recommends that if a dog develops new or increased joint swelling or joint pain whilst on Librela, this should prompt additional diagnostic investigations and consideration of discontinuing treatment.

This represents a significant shift towards more cautious monitoring, recognising that whilst serious adverse effects remain rare, their potential severity requires proactive surveillance and early intervention when warning signs appear.

Making Treatment Decisions

If you're considering Librela for your dog, thorough discussion with your vet about suitability is essential. Certain factors may increase the risk of adverse effects or make alternative treatments more appropriate.

Dogs Who May Not Be Suitable

Your vet will carefully assess whether Librela is appropriate, particularly if your dog has pre-existing neurological conditions, significant joint instability, severe structural joint disease, a history of fractures, or immune-mediated conditions. Older dogs may require particularly careful consideration given the higher frequency of neurological events in this age group.

The decision should also consider your dog's overall health status, concurrent medications, and whether the monthly injection schedule fits with your routine and preferences. If you're unsure about treatment options, discussing all available approaches with your vet can help clarify the best path forward.

Weighing Benefits and Risks

For many dogs, Librela provides significant quality of life improvements that outweigh the small risk of serious adverse effects. Dogs who have struggled with gastrointestinal side effects from NSAIDs, those requiring long-term pain management, or cases where daily medication administration is challenging may particularly benefit from this treatment option.

However, the recent safety data emphasises that this decision should never be taken lightly. Your vet should explain both the potential benefits and risks clearly, ensuring you understand what to monitor for at home.

Monitoring Your Dog During Treatment

Successful Librela treatment requires active monitoring from both you and your veterinary team. Regular assessment helps ensure your dog is benefiting from treatment whilst catching any concerning changes early.

What to Watch for at Home

Pay particular attention to your dog's gait and mobility between injections. Contact your vet immediately if you notice new or worsening unsteadiness (especially in the hind legs), any seizures or neurological changes, partial paralysis or weakness, changes in urination patterns, excessive thirst, or new joint swelling or pain.

Also monitor your dog's overall response to treatment. Are they clearly more comfortable? Has mobility genuinely improved? Are they more willing to exercise or play? If the response has been limited after several months, discuss alternatives with your vet.

Veterinary Monitoring

Your vet should schedule regular check-ups to assess your dog's response and monitor for any developing concerns. These appointments typically include gait assessment, joint examination for swelling or pain, neurological evaluation, and discussion of your observations at home.

The frequency of monitoring may vary based on your dog's age, health status, and response to treatment, but should occur at least every few months for dogs on long-term therapy. For senior dogs, comprehensive health checks become even more important during treatment.

Complementary Support for Joint Health

Whilst Librela addresses pain signals, supporting your dog's joint health through other means can provide additional benefits. Joint supplements containing ingredients like glucosamine, chondroitin, and omega-3 fatty acids work differently to Librela, supporting cartilage health and providing anti-inflammatory effects.

MedPaw's hip and joint supplement combines key joint actives including glucosamine, chondroitin, MSM, green-lipped mussel, hyaluronic acid, and Boswellia serrata. These daily soft chews also provide omega-3 from green-lipped mussel and flax seed, plus vitamins C and E, and zinc to support overall joint function alongside veterinary treatments.

Physiotherapy, controlled exercise, weight management, and environmental modifications can also play important roles in managing arthritis. These supportive approaches work well alongside prescription treatments and may help optimise your dog's comfort and mobility.

Discussing Combined Approaches

Many dogs in concerning case studies were receiving both Librela and NSAIDs concurrently. Whilst this combination hasn't been proven to increase risk, discuss with your vet whether both treatments are truly necessary for your dog's specific situation.

A comprehensive approach might include Librela for pain management, joint supplements for cartilage support, and lifestyle modifications for overall joint health. Your vet can help design the most appropriate combination for your dog's individual needs.

The Future of Librela

Librela represents an important advancement in canine arthritis management, offering hope for dogs who haven't responded well to traditional treatments. The novel mechanism of action has genuinely helped many dogs achieve better quality of life with reduced pain and improved mobility.

However, the emerging safety data highlights the importance of careful patient selection, ongoing monitoring, and informed consent from owners. Like all effective medications, Librela carries some risk of adverse effects in certain patients, and these risks must be weighed against potential benefits for each individual dog.

The veterinary profession continues to learn about optimal use of this treatment through ongoing research and post-market surveillance. This evolving understanding helps refine guidelines for patient selection and monitoring, ultimately improving outcomes for dogs receiving treatment.

Making Informed Decisions

Success with Librela depends on appropriate patient selection, regular monitoring, and maintaining open communication with your veterinary team about your dog's response to treatment. Never stop any prescribed medication without consulting your vet first, as sudden discontinuation could lead to return of pain and discomfort.

If you have concerns about Librela or your dog's joint health, discuss them openly at your next veterinary appointment. Your vet can help you understand whether this treatment is appropriate for your dog's specific situation and what alternatives might be available if needed.

Remember that joint health is a long-term consideration requiring ongoing management. Whether through prescription treatments like Librela, supportive supplements, or lifestyle modifications, the goal remains the same: keeping your dog comfortable, mobile, and enjoying the best possible quality of life throughout their golden years.